Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Establishment and characterization of a novel murine model of pancreatic cancer cachexia
2017
Contributing Knowledge to Electronic Knowledge Repositories: An Empirical Investigation1
2005 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
The views and practice of oncologists towards nutritional support in patients receiving chemotherapy
2006
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
The EGF receptor family as targets for cancer therapy
2000
Altered fecal microbiota composition in patients with major depressive disorder
2015 Standout
Identification of an immune-responsive mesolimbocortical serotonergic system: Potential role in regulation of emotional behavior
2007
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
2006 Standout
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
2007 Standout
Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: A systematic review
2015
Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force
2014
Assessment of tumor response in malignant pleural mesothelioma
2007
Targeting epidermal growth factor receptor in head and neck cancer
2002
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Ovarian cancer
2014 Standout
Colonisation ofClostridiumin the body is restricted to hypoxic and necrotic areas of tumours
1998
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy ,
2017
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
1997
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Management of malignant pleural mesothelioma: a critical review
2000
The hygiene hypothesis and psychiatric disorders
2008
Cancer cachexia: Developing multimodal therapy for a multidimensional problem
2008
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
2016
New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
2002
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Photodynamic therapy for cancer
2003 Standout
Engineering the perfect (bacterial) cancer therapy
2010 Standout
EGF–ERBB signalling: towards the systems level
2006 Standout
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients
2008
Understanding the mechanisms and treatment options in cancer cachexia
2012
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Cancer-associated cachexia
2018 Standout
Cancer genes and the pathways they control
2004 Standout
Technetium‐99m labeled epidermal growth factor‐tumor imaging in mice
1997
Advances in the Treatment of Malignant Pleural Mesothelioma
1999
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
1999
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
2002
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial
1999
The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease
2011 Standout
Chemotherapy for Malignant Pleural Mesothelioma
2003
Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis
2006
Overview of the clinical efficacy of investigational anticancer drugs
2003
PI3K/Akt signalling pathway and cancer
2003 Standout
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
2010
Induction of CD8 T-cell-Ifn-γ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma
2003
Integration of EGFR inhibitors with radiochemotherapy
2006
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
1999 Standout
Infection, immunoregulation, and cancer
2011
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Can we vaccinate against depression?
2012
Advances in Malignant Mesothelioma
2005 Standout
Anemia of Chronic Disease
2005 Standout
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807)
2003
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
1999
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy.
1999
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
2006 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?
2008 Standout
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Chemotherapy Use among Medicare Beneficiaries at the End of Life
2003
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
On Organizational Becoming: Rethinking Organizational Change
2002 Standout
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
NK cell–mediated killing of target cells triggers robust antigen-specific T cell–mediated and humoral responses
2009 StandoutNobel
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
2005 Standout
Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy
2003
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis
2017
Cracking the code of change.
2001
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of K. Priest being referenced
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
2004
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
2005
Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
1996
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
2004
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma
1998
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
1995
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma
2000
75 Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma
1997